Naratriptan is a 5-HT1B/1D receptor agonist used to treat migraines. Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype.
- Mechanism
- Curator reviewed
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
- Primary indication
- For the acute treatment of migraine attacks with or without aura in adults.Curator reviewed · 2 structured indications
- Formula / weight
- C17H25N3O2S · 335.464 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1998
Resolves to
AMKVXSZCKVJAGH-UHFFFAOYSA-NSMILESCNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Naratriptan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account